Kai Wang1,2, Fusheng Shang3, Dagui Chen3, Tieliu Cao4, Xiaowei Wang5, Jianpeng Jiao5, Shengli He6, Xiaofei Liang7. 1. State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, 200032, People's Republic of China. 2. Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Public Health Clinical Center, Shanghai Medical College, Fudan University, Shanghai, 200032, People's Republic of China. 3. Institute of Translational Medicine, Shanghai University, Shanghai, 200444, People's Republic of China. 4. Department of Hepatobiliary-pancreatic and Integrative Oncology, Minhang Branch, Fudan University Shanghai Cancer Center, Shanghai, 200240, People's Republic of China. 5. Department of traditional Chinese medicine, Changzheng Hospital, Shanghai, 200001, People's Republic of China. 6. Department of Hepatobiliary-pancreatic and Integrative Oncology, Minhang Branch, Fudan University Shanghai Cancer Center, Shanghai, 200240, People's Republic of China. hsl1024@yeah.net. 7. State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, 200032, People's Republic of China. xfliang2019@163.com.
Abstract
BACKGROUND: Effective methods to deliver therapeutic genes to solid tumors and improve their bioavailability are the main challenges of current medical research on gene therapy. The development of efficient non-viral gene vector with tumor-targeting has very important application value in the field of cancer therapy. Proteolipid integrated with tumor-targeting potential of functional protein and excellent gene delivery performance has shown potential for targeted gene therapy. RESULTS: Herein, we prepared transferrin-modified liposomes (Tf-PL) for the targeted delivery of acetylcholinesterase (AChE) therapeutic gene to liver cancer. We found that the derived Tf-PL/AChE liposomes exhibited much higher transfection efficiency than the commercial product Lipo 2000 and shown premium targeting efficacy to liver cancer SMMC-7721 cells in vitro. In vivo, the Tf-PL/AChE could effectively target liver cancer, and significantly inhibit the growth of liver cancer xenografts grafted in nude mice by subcutaneous administration. CONCLUSIONS: This study proposed a transferrin-modified proteolipid-mediated gene delivery strategy for targeted liver cancer treatment, which has a promising potential for precise personalized cancer therapy.
BACKGROUND: Effective methods to deliver therapeutic genes to solid tumors and improve their bioavailability are the main challenges of current medical research on gene therapy. The development of efficient non-viral gene vector with tumor-targeting has very important application value in the field of cancer therapy. Proteolipid integrated with tumor-targeting potential of functional protein and excellent gene delivery performance has shown potential for targeted gene therapy. RESULTS: Herein, we prepared transferrin-modified liposomes (Tf-PL) for the targeted delivery of acetylcholinesterase (AChE) therapeutic gene to liver cancer. We found that the derived Tf-PL/AChE liposomes exhibited much higher transfection efficiency than the commercial product Lipo 2000 and shown premium targeting efficacy to liver cancerSMMC-7721 cells in vitro. In vivo, the Tf-PL/AChE could effectively target liver cancer, and significantly inhibit the growth of liver cancer xenografts grafted in nude mice by subcutaneous administration. CONCLUSIONS: This study proposed a transferrin-modified proteolipid-mediated gene delivery strategy for targeted liver cancer treatment, which has a promising potential for precise personalized cancer therapy.
Authors: Angelo M De Marzo; Elizabeth A Platz; Siobhan Sutcliffe; Jianfeng Xu; Henrik Grönberg; Charles G Drake; Yasutomo Nakai; William B Isaacs; William G Nelson Journal: Nat Rev Cancer Date: 2007-04 Impact factor: 60.716
Authors: Ludmil B Alexandrov; Young Seok Ju; Kerstin Haase; Peter Van Loo; Iñigo Martincorena; Serena Nik-Zainal; Yasushi Totoki; Akihiro Fujimoto; Hidewaki Nakagawa; Tatsuhiro Shibata; Peter J Campbell; Paolo Vineis; David H Phillips; Michael R Stratton Journal: Science Date: 2016-11-04 Impact factor: 47.728
Authors: Adel Samson; Matthew J Bentham; Karen Scott; Gerard Nuovo; Abigail Bloy; Elizabeth Appleton; Robert A Adair; Rajiv Dave; Adam Peckham-Cooper; Giles Toogood; Seishi Nagamori; Matthew Coffey; Richard Vile; Kevin Harrington; Peter Selby; Fiona Errington-Mais; Alan Melcher; Stephen Griffin Journal: Gut Date: 2016-11-15 Impact factor: 23.059
Authors: Frances Connor; Tim F Rayner; Sarah J Aitken; Christine Feig; Margus Lukk; Javier Santoyo-Lopez; Duncan T Odom Journal: J Hepatol Date: 2018-06-26 Impact factor: 25.083
Authors: Alexis Eras; Danna Castillo; Margarita Suárez; Nelson Santiago Vispo; Fernando Albericio; Hortensia Rodriguez Journal: Front Chem Date: 2022-05-26 Impact factor: 5.545